User: Guest  Login
Less Searchfields
Simple search
Title:

Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.

Document type:
Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Article
Author(s):
Hauschild, A; Weichenthal, M; Balda, BR; Becker, JC; Wolff, HH; Tilgen, W; Schulte, KW; Ring, J; Schadendorf, D; Lischner, S; Burg, G; Dummer, R
Abstract:
PURPOSE: Low-dose interferon alfa (IFNalpha) has been shown to have limited effects in the adjuvant treatment of patients with intermediate- and high-risk primary melanoma. We hypothesized that a combination regimen with low-dose interleukin-2 (IL-2) may improve survival prospects in these patients. PATIENTS AND METHODS: After wide excision of primary melanoma without clinically detectable lymph node metastasis (pT3 to 4, cN0, M0), 225 patients from 10 participating centers were randomly assigne...     »
Journal title abbreviation:
J Clin Oncol
Year:
2003
Journal volume:
21
Journal issue:
15
Pages contribution:
2883-8
Language:
eng
Fulltext / DOI:
doi:10.1200/JCO.2003.07.116
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/12885805
Print-ISSN:
0732-183X
TUM Institution:
Klinik und Poliklinik für Dermatologie und Allergologie
 BibTeX